PMID-40961952 — STEP UP: Semaglutide 7.2 mg in Obesity (Phase 3b, Lancet Diabetes Endocrinol 2025)

[DRAFT — authored 2026-04-20. Citation verified against PubMed/Lancet Diabetes Endocrinol 2026-04-20.]

Citation

Wharton S, Blüher M, Davies MJ, Deanfield J, Garvey WT, Hansen TL, Hesse D, Jastreboff AM, Kushner RF, Lingvay I, Panigrahi S, Rubino D, Wadden TA, Warren M, Busetto L; STEP UP Trial Group. Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. 2025;13(11):949-963. doi: 10.1016/S2213-8587(25)00234-3. PMID: 40961952. NCT05646706.

External URL: PubMed

Study Design

Design: Randomised, double-blind, placebo-controlled, parallel-group Phase 3b trial
Allocation: 5:1:1 (semaglutide 7.2 mg : semaglutide 2.4 mg : placebo)
Setting: 95 sites across 11 countries
N: 1,407 participants (7.2 mg: 1,005; 2.4 mg: 201; placebo: 201)
Population: Adults BMI ≥30 kg/m² (or ≥27 + ≥1 weight-related comorbidity) without type 2 diabetes
Baseline: 73.7% female, mean age 47, mean weight 113.0 kg, mean BMI 39.9 kg/m²
Intervention: Once-weekly SC semaglutide 7.2 mg, 2.4 mg, or matching placebo + lifestyle intervention
Duration: 72 weeks treatment
Primary endpoint: Percent change in body weight from baseline to week 72

Key Findings

Weight loss at 72 weeks

Arm	Mean body weight change
Semaglutide 7.2 mg	−18.7%
Semaglutide 2.4 mg	−15.6%
Placebo	−3.9%

Weight-loss category odds (7.2 mg vs placebo)

≥5% loss: 12.1× more likely
≥10% loss: 14.5× more likely
≥20% loss: 27.3× more likely
≥25% loss: 127.4× more likely

Safety

GI adverse events: 70.8% (7.2 mg) vs 42.8% (placebo) — higher than 2.4 mg as expected with higher dose
Dysesthesia: 22.9% (7.2 mg) vs 0.5% (placebo) — a substantially elevated signal; new label feature for 7.2 mg
Serious adverse events: 6.8% (7.2 mg) vs 5.5% (placebo) — comparable

Clinical Relevance

STEP UP is the pivotal Phase 3b trial supporting the FDA approval of Wegovy 7.2 mg (higher-dose semaglutide) on March 19, 2026 via the National Priority Voucher Program (fourth NPV-approved product, 54-day review). EMA CHMP issued a positive opinion on December 12, 2025.

Key teaching points:

7.2 mg is substantially more effective than 2.4 mg in non-T2D obesity at 72 weeks (−18.7% vs −15.6%). Absolute difference of 3.1 percentage points; relative gain ~20%.
Dysesthesia (~22.9%) is the defining new AE profile feature of the higher-dose — clinicians must counsel explicitly and document baseline neurologic exam before escalation.
Titration requirement: Patients must tolerate 2.4 mg for ≥4 weeks before escalating to 7.2 mg per FDA label.
Narrowing the gap with tirzepatide 15 mg: Cross-trial comparison places 7.2 mg at −18.7% vs tirzepatide 15 mg at −22.5% (SURMOUNT-1). Still no head-to-head RCT; do not infer clinical equivalence.

Linked Peptides

Semaglutide

Related Lessons

Lesson 5.2 — Semaglutide Deep Dive (Wegovy HD section)
Lesson 5.4 — Regulatory timeline of semaglutide expansion

Related Studies

PMID-40961953 – STEP UP T2D Lingvay Semaglutide 7.2 mg — T2D companion trial
REG-FDA-Wegovy-HD-2026 – Wegovy 7.2 mg National Priority Voucher Approval — FDA approval regulatory note
REG-EMA-Wegovy-7-2mg-CHMP-Opinion-2025 – CHMP Positive Opinion — EMA CHMP opinion
PMID-33567185 – Once-Weekly Semaglutide in Adults with Overweight or Obesity — STEP 1 (2.4 mg benchmark)

PMID-40961952 – STEP UP Wharton Semaglutide 7.2 mg Obesity